Historic license for an Alzheimer's drug

US drugmaker Biogen has received approval from the US Food and Drug Administration to use the controversial drug aducanumab to treat Alzheimer's disease, a landmark decision that will dramatically change the way it treats deteriorating brain condition.

And after decades of research by drug companies failed to discover a cure for Alzheimer's disease, aducanumab became the first drug to be approved by the US Food and Drug Administration for use in slowing the decline in cognitive abilities in Alzheimer's patients.

The antibody-based drug, which will be marketed under the brand name "Adohelm", works by removing amyloid, a harmful protein that causes clotting in the brains of Alzheimer's patients.

And “Bloomberg” explained that the last time a new drug was approved for Alzheimer’s disease was in 2003, noting that available treatments on the market help treat symptoms, but do not reduce the basic damage of the disease.

And the US Food and Drug Administration announced in a statement yesterday that it had approved the use of the drug "Aducanumab" for the treatment of Alzheimer's disease.

"Given that the drug meets urgent approval requirements, we concluded that the benefits of ADHOhelm for people with Alzheimer's disease outweigh the risks," she said.

This approval represents one of the most important decisions of the Food and Drug Administration in recent years, as it has been welcomed by millions of Americans with Alzheimer's disease and their families.